Current concepts of neuroendocrine cancer of the prostate: a clinical case and review of the literature

Author:

Chizh Grigoriy A.ORCID,Tyutrina Yuliya A.ORCID,Protsenko Svetlana A.ORCID,Dzhelialov Ernest S.ORCID,Latipova Dilorom H.ORCID

Abstract

Prostate cancer (PC) is a heterogeneous group of diseases that differ in their biological nature, clinical manifestations, and prognosis. A special variant among them is a neuroendocrine prostate cancer (NEPC). NEPC is a rare disease with unfavorable prognosis. The majority of patients with different NEPC variants die within 2 years after the diagnosis, despite the performed treatment. The distinctive features of NEPC are the patterns of metastasis in the form of a tendency to involve internal organs and extra regional lymph nodes, lytic bone lesions; high rates (up to 6 months) of clinical and radiological disease progression against the background of androgen-deprivation therapy; expression of serological markers and their high content in peripheral blood. The reasons of the aggressive behavior of NEPC consists in molecular and genetic events in cells, leading to realization of androgen-independent mechanisms of proliferation as a result of the AURKA-mediated neuroendocrine differentiation of tumor cells, early loss of function of p53 and Rb1 oncosuppressors, and low expression of androgen receptors. In every tenth case of NEPC, these molecular changes are response of prostatic adenocarcinoma to androgen-deprivation therapy. The described clinical case demonstrates the differences of biological behavior of these cancer variants and their sensitivity to various variants of drug treatment. Our case also illustrates possible difficulties of differential diagnostics of prostatic adenocarcinoma with various variants of neuroendocrine cancer, especially with adenocarcinoma with foci of neuroendocrine differentiation. The complexity of management of patients with NEPC are exacerbated by insufficient coverage of this problem: the existing data on the management of patients suffering from various variants of NEPC are limited by descriptions of clinical cases, literature reviews and few phases III clinical studies. All this makes it necessary to thoroughly study and describe each case of NEPC.

Publisher

Consilium Medicum

Subject

Cancer Research,Oncology

Reference45 articles.

1. Abbas F, Civantos F, Benedetto P, et al. Small cell carcinoma of the bladder and prostate. Urology. 1995;46(5):617-30.

2. Сивков А.В., Кешишев Н.Г., Ефремов Г.Д., и др. Нейроэндокринная дифференцировка рака предстательной железы, что нового? Экспериментальная и клиническая урология. 2015;3:22-30 [Sivkov AV, Keshishev NG, Efremov GD, et al. Neiroendokrinnaia differentsirovka raka predstatel'noi zhelezy, chto novogo? Eksperimental'naia i klinicheskaia urologiia. 2015;3:22-30 (in Russian)].

3. Therapy considerations in neuroendocrine prostate cancer: what next?

4. Ionizing Radiation Induces Prostate Cancer Neuroendocrine Differentiation through Interplay of CREB and ATF2: Implications for Disease Progression

5. Patel GK, Chugh N, Tripathi M. Neuroendocrine Differentiation of Prostate Cancer – An Intriguing Example of Tumor Evolution at Play. Cancers (Basel). 2019;11(10):1405.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3